Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q3 2018 · 10-Q
Revenue$379.00K$379.00K+24.3% vs Q3 2017 Net Income-$17.34M-$17.34MN/M vs Q3 2017 EPS Diluted$0.68$0.68N/M vs Q3 2017 Operating Income-$17,841,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$18,469,000— Margins · derivedOperating margin-4707.4%+356.9 pt vs Q3 2017
Net margin-4574.7%+372.2 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 5, 2018 · 36 d after period end